{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:31:13Z","timestamp":1791156673989,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Sanofi U.S. LLC"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.ygyno.2014.01.035","type":"journal-article","created":{"date-parts":[[2014,1,27]],"date-time":"2014-01-27T07:15:42Z","timestamp":1390806942000},"page":"517-525","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube"],"prefix":"10.1016","volume":"132","clinical-trial-number":[{"clinical-trial-number":"nct00296816","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Thomas J.","family":"Herzog","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley J.","family":"Monk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Braly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey F.","family":"Hines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C.","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Wenham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angeles Alvarez","family":"Secord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda D.","family":"Roman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark H.","family":"Einstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Drake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barrett H.","family":"Childs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2014.01.035_bb0005","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.ygyno.2014.01.035_bb0010","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/IGC.0b013e31821b2568","article-title":"2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference","volume":"21","author":"Stuart","year":"2011","journal-title":"Int J Gynecol Cancer"},{"issue":"8","key":"10.1016\/j.ygyno.2014.01.035_bb0015","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/annonc\/mdm136","article-title":"Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study","volume":"18","author":"Ferrandina","year":"2007","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ygyno.2014.01.035_bb0020","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1111\/IGC.0b013e3181b62f38","article-title":"Phase 2 trial of docetaxel, gemcitabine, and oxaliplatin combination chemotherapy in platinum- and paclitaxel-pretreated epithelial ovarian cancer","volume":"19","author":"Seliger","year":"2009","journal-title":"Int J Gynecol Cancer"},{"issue":"22","key":"10.1016\/j.ygyno.2014.01.035_bb0025","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/jnci\/djh323","article-title":"Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma","volume":"96","author":"Vasey","year":"2004","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"10.1016\/j.ygyno.2014.01.035_bb0030","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1023\/A:1012556627852","article-title":"Multicenter phase II-III study of oxaliplatin plus cyclophosphamide vs. cisplatin plus cyclophosphamide in chemonaive advanced ovarian cancer patients","volume":"12","author":"Misset","year":"2001","journal-title":"Ann Oncol"},{"issue":"33","key":"10.1016\/j.ygyno.2014.01.035_bb0035","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Burger","year":"2007","journal-title":"J Clin Oncol"},{"issue":"33","key":"10.1016\/j.ygyno.2014.01.035_bb0040","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer","volume":"25","author":"Cannistra","year":"2007","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ygyno.2014.01.035_bb0045","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1525-1438.2007.00886.x","article-title":"A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer","volume":"17","author":"Micha","year":"2007","journal-title":"Int J Gynecol Cancer"},{"issue":"26","key":"10.1016\/j.ygyno.2014.01.035_bb0050","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.ygyno.2014.01.035_bb0055","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ygyno.2014.01.035_bb0060","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.ygyno.2014.01.035_bb0065","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/jnci\/djh081","article-title":"Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)","volume":"96","author":"Rustin","year":"2004","journal-title":"J Natl Cancer Inst"},{"issue":"20","key":"10.1016\/j.ygyno.2014.01.035_bb0075","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1200\/JCO.2000.18.20.3558","article-title":"2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel","volume":"18","author":"Ozer","year":"2000","journal-title":"J Clin Oncol"},{"issue":"282","key":"10.1016\/j.ygyno.2014.01.035_bb0080","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Non parametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.ygyno.2014.01.035_bb0085","author":"National Cancer Institute"},{"key":"10.1016\/j.ygyno.2014.01.035_bb0090","series-title":"Cancer Management: A Multidisciplinary Approach","article-title":"Ovarian cancer","author":"Rubin","year":"2011"},{"issue":"1","key":"10.1016\/j.ygyno.2014.01.035_bb0095","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1200\/JCO.2009.22.7900","article-title":"Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors","volume":"28","author":"Penson","year":"2010","journal-title":"J Clin Oncol"},{"issue":"35","key":"10.1016\/j.ygyno.2014.01.035_bb0100","doi-asserted-by":"crossref","first-page":"4662","DOI":"10.1200\/JCO.2011.36.1352","article-title":"Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II\/III epithelial ovarian cancer","volume":"29","author":"Konner","year":"2011","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ygyno.2014.01.035_bb0105","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2008.19.1684","article-title":"Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup","volume":"27","author":"Bookman","year":"2009","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.ygyno.2014.01.035_bb0110","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J Clin Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581400095X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581400095X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T13:32:53Z","timestamp":1620826373000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082581400095X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S009082581400095X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2014.01.035","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2014.01.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}